ImmunityBio (IBRX) Stock Chart & Stock Price History $2.26 -0.05 (-1.95%) As of 01:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ImmunityBio Stock Price Performance The ImmunityBio (IBRX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 46.71%, with a year-to-date return of -11.52%. In the past month, the stock has decreased 20.80%, reflecting recent market activity. As of the latest close, ImmunityBio traded at $2.31 with a market cap of $2.18 billion and volume of 9.52 million shares. Receive IBRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+0.22%1 Month Performance-20.80%3 Month Performance-10.47%Year-To-Date Performance-11.52%1 Year Performance-46.71% IBRX Stock Chart for Monday, August, 25, 2025 IBRX Chart by TradingView ImmunityBio Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/22/2025$2.24$2.31+3.12%$2.35$2.239.52 million shs$2.18 billion08/21/2025$2.26$2.24-0.88%$2.27$2.215.67 million shs$2.12 billion08/20/2025$2.28$2.26-0.88%$2.32$2.177.52 million shs$2.14 billion08/19/2025$2.43$2.28-6.17%$2.44$2.2610.15 million shs$2.16 billion08/18/2025$2.55$2.43-4.71%$2.55$2.3812.13 million shs$2.30 billion08/15/2025$2.71$2.55-5.90%$2.72$2.549.76 million shs$2.41 billion08/14/2025$2.82$2.71-3.90%$2.79$2.649.71 million shs$2.56 billion08/13/2025$2.47$2.82+14.17%$2.94$2.5530.79 million shs$2.67 billion08/12/2025$2.47$2.47$2.54$2.457.46 million shs$2.33 billion08/11/2025$2.44$2.47+1.23%$2.64$2.469.02 million shs$2.33 billion Get the Latest News and Ratings for IBRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter. 08/08/2025$2.40$2.44+1.67%$2.44$2.384.74 million shs$2.15 billion08/07/2025$2.38$2.40+0.84%$2.44$2.347.91 million shs$2.12 billion08/06/2025$2.41$2.38-1.24%$2.44$2.334.08 million shs$2.10 billion08/05/2025$2.41$2.41$2.46$2.366.13 million shs$2.13 billion08/04/2025$2.37$2.41+1.69%$2.45$2.336.54 million shs$2.13 billion08/01/2025$2.46$2.37-3.66%$2.42$2.347.04 million shs$2.09 billion07/31/2025$2.56$2.46-3.91%$2.57$2.447.90 million shs$2.17 billion07/30/2025$2.54$2.56+0.79%$2.67$2.547.09 million shs$2.26 billion07/29/2025$2.65$2.54-4.15%$2.67$2.537.11 million shs$2.24 billion07/28/2025$2.86$2.65-7.34%$2.91$2.659.87 million shs$2.34 billion07/25/2025$3.01$2.86-4.98%$3.11$2.8119.84 million shs$2.52 billion07/24/2025$2.99$3.01+0.67%$3.07$2.907.26 million shs$2.66 billion Related Companies ROIV Stock Price Chart GRFS Stock Price Chart RVMD Stock Price Chart LEGN Stock Price Chart RYTM Stock Price Chart RGC Stock Price Chart AXSM Stock Price Chart RNA Stock Price Chart NUVL Stock Price Chart ABVX Stock Price Chart Receive IBRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:IBRX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access